The psychopharmacology department at Maastricht University focuses on the cognitive, behavioral, and biological effects of various substances, ranging from pharmaceutical to recreational drugs
New study from our group assessed cognitive and subjective effects of a synthetic cannabinoid, JWH-018. Read coverage of the publication from Live Science.
March 25, 2019. Researchers from IMIM (Barcelona) and our department employed the quantification of monoamine neurotransmitters and steroid hormones in brain tissue and blood of rats to predict the pharmacological similarity of NPS to classical drugs of abuse. The metabolomics approach in animals improves the speed of NPS classification.
After many years of animal research, in which we found that inhibition of the enzyme phosphodiesterase type 4 (PDE4) improved memory in animals, we now find first evidence that this mechanism also works in humans. In this study, we tested how many words older participants (aged between 60 and 85 years old) could remember from… Continue reading Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study
New Rochelle, NY, March 19, 2019—A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation. The results of this placebo controlled, cross-over study are published in Cannabis and Cannabinoid Research, a peer-reviewed… Continue reading Even Low Doses of Synthetic Cannabinoids Can Impair Cognitive Performance
New research from our group provides more evidence that psilocybin, the active ingredient in magic mushrooms, can improve creative thinking, empathy, and subjective well-being. Read more here, here ,and here.